Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001213900-22-010081
Filing Date
2022-03-01
Accepted
2022-03-01 16:37:43
Documents
62
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 ANNUAL REPORT f10k2021_rasnathera.htm   iXBRL 10-K 1405268
2 LIST OF SUBSIDIARIES f10k2021ex21_rasnathera.htm EX-21 904
3 CERTIFICATION f10k2021ex31-1_rasnathera.htm EX-31.1 16230
4 CERTIFICATION f10k2021ex31-2_rasnathera.htm EX-31.2 16699
5 CERTIFICATION f10k2021ex32-1_rasnathera.htm EX-32.1 5864
6 CERTIFICATION f10k2021ex32-2_rasnathera.htm EX-32.2 6224
7 GRAPHIC img_001.jpg GRAPHIC 58312
  Complete submission text file 0001213900-22-010081.txt   5282868

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE rasp-20210930.xsd EX-101.SCH 40852
9 XBRL CALCULATION FILE rasp-20210930_cal.xml EX-101.CAL 25621
10 XBRL DEFINITION FILE rasp-20210930_def.xml EX-101.DEF 180756
11 XBRL LABEL FILE rasp-20210930_lab.xml EX-101.LAB 383130
12 XBRL PRESENTATION FILE rasp-20210930_pre.xml EX-101.PRE 195274
56 EXTRACTED XBRL INSTANCE DOCUMENT f10k2021_rasnathera_htm.xml XML 644062
Mailing Address 420 LEXINGTON AVENUE SUITE 2525 NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE SUITE 2525 NEW YORK NY 10170 646-396-4087
Rasna Therapeutics Inc. (Filer) CIK: 0001582249 (see all company filings)

EIN.: 392080103 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 10-K | Act: 34 | File No.: 333-191083 | Film No.: 22698809
SIC: 2834 Pharmaceutical Preparations